Suraksha Diagnostic Limited Q4 FY25 results press release summary

Results press release of 28 May 2025, summarised by AI from the filing.

Management anticipates adding 15-18 centers in FY26, with approvals in place for majority of planned centers.

Key takeaways

1. FY26 guidance Management anticipates adding 15-18 centers in FY26, with approvals in place for majority of planned centers.
2. Growth driver Revenue growth from operations and center additions; 7 centers added in FY25.
3. Risk Management focus on IPO and unfavorable events such as doctors’ strike and Bangladesh issue affected operations.

Original filing on BSE

Suraksha Diagnostic Limited Q1 FY27 results

As filed: Revenue ₹87.7 cr (+20% year on year), EBITDA ₹30.4 cr (+32% year on year), PAT ₹12.9 cr (+43% year on year), EBITDA margin 34.7% (+322 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹81.4 cr (+25% year on year), EBITDA ₹24.4 cr (+28% year on year), PAT ₹6.2 cr (−12% year on year), EBITDA margin 29.9% (+70 bps). Score 56 of 100, In line with trend. EBITDA margin rose 70 bps year on year. Tax rate 38%. Not enough history for a trend yet: scored on growth alone. Profit fell 15% from last quarter. Share price after the results: −16.2% in 29 days (Nifty 500: +2.4%).
• Q3 FY26: Revenue ₹77.7 cr (+29% year on year), EBITDA ₹23.2 cr (+29% year on year), PAT ₹7.2 cr (+21% year on year), EBITDA margin 29.8% (−19 bps). Score 70 of 100, Above trend. EBITDA margin fell 19 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 20% from last quarter. Share price after the results: −9.7% in 29 days (Nifty 500: −4.0%).
• Q2 FY26: Revenue ₹79.0 cr (+18% year on year), EBITDA ₹24.0 cr (0% year on year), PAT ₹9.0 cr (−10% year on year), EBITDA margin 30.4% (−544 bps). Score 36 of 100, Below trend. EBITDA margin fell 544 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −13.0% in 30 days (Nifty 500: −0.8%).
• Q1 FY26: Revenue ₹70.0 cr, EBITDA ₹24.0 cr, PAT ₹10.0 cr, EBITDA margin 34.3%. Not scored. No result for the same quarter last year. Share price after the results: +0.9% in 28 days (Nifty 500: +1.7%).
• Q4 FY25: Revenue ₹64.0 cr, EBITDA ₹20.0 cr, PAT ₹8.0 cr, EBITDA margin 31.3%. Not scored. No result for the same quarter last year. Share price after the results: −1.7% in 30 days (Nifty 500: +3.7%).
• Q3 FY25: Revenue ₹59.0 cr, EBITDA ₹18.0 cr, PAT ₹6.0 cr, EBITDA margin 30.5%. Not scored. No result for the same quarter last year.
• Q2 FY25: Revenue ₹66.0 cr, EBITDA ₹24.0 cr, PAT ₹11.0 cr, EBITDA margin 36.4%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Suraksha Diagnostic Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (13 Aug 2026), Results deck (12 Aug 2026), Results press release (12 Aug 2026)
• Q4 FY26: Earnings call (22 May 2026), Results deck (21 May 2026), Results press release (21 May 2026)
• Q3 FY26: Earnings call (6 Feb 2026), Results deck (5 Feb 2026), Results press release (5 Feb 2026)
• Q2 FY26: Earnings call (11 Nov 2025), Results deck (10 Nov 2025), Results press release (10 Nov 2025)
• Q1 FY26: Earnings call (11 Aug 2025), Results deck (9 Aug 2025), Results press release (8 Aug 2025)
• Q4 FY25: Earnings call (30 May 2025), Results deck (29 May 2025), Results press release (28 May 2025)